Corticosteroid use and the risk of glaucoma: A systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v13i12.47453

Keywords:

Glaucoma; Intraocular Pressure; Corticoid.

Abstract

Glaucoma is an optic neuropathy considered to be the second leading cause of vision loss in the world. Elevated intraocular pressure seems to be the main risk factor for the condition related to corticosteroids. The objective of this article was to carry out a literature review to analyze the relationship between the use of corticosteroids and the risk of glaucoma. A search was carried out in the electronic databases PubMed, SciELO, and LILACS, obtaining a total of 5090 articles. After selection based on inclusion and exclusion criteria, 15 articles were obtained as a sample. The main corticoid described was dexamethasone, in the form of an intravitreal implant. The average follow-up time was 12 months, after stopping the use of glucocorticoids, intraocular pressure returned to baseline values. It is concluded that ophthalmological follow-up of patients taking glucocorticoids is necessary to prevent persistent high levels of intraocular pressure from causing irreversible sequelae.

References

American Academy of Ophthalmology (AAO). (2024). Steroid-induced glaucoma. EyeWiki. Retrieved from https://eyewiki.aao.org/Steroid-Induced_Glaucoma

Badrinarayanan, L., et al. (2022). Incidence, risk factors, treatment, and outcome of ocular hypertension following intravitreal steroid injections: A comparative study. Ophthalmologica, 245(5), 431-438.

Barzilai-Birenboim, S., et al. (2022). Age as a risk factor for steroid-induced ocular hypertension in the non-pediatric population. British Journal of Haematology, 196(5), 1248-1256.

Cassetti, R. B., et al. (2017). Increased synthesis and deposition of extracellular matrix proteins leads to endoplasmic reticulum stress in the trabecular meshwork. Scientific Reports, 7, 14951.

Choi, M. Y., & Kwon, J. W. (2020a). Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema. Scientific Reports, 10(1), 13736.

Choi, W., et al. (2020b). Age as a risk factor for steroid-induced ocular hypertension in the non-pediatric population. British Journal of Ophthalmology, 104(10), 1423-1429.

Choi, W., et al. (2022a). Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation. British Journal of Ophthalmology, 106(8), 1150-1156.

Choi, W., et al. (2022b). Axial length as a risk factor for steroid-induced ocular hypertension. Yonsei Medical Journal, 63(9), 850-855.

Dibas, A., & Yorio, T. (2016). Glucocorticoid therapy and ocular hypertension. European Journal of Pharmacology, 787, 57-71.

Dietze, J., et al. (2024). Glaucoma. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

Gomes, I. S., & Caminha, I. O. (2014). Guia para estudos de revisão sistemática: Uma opção metodológica para as Ciências do Movimento Humano. Movimento, 20(1), 395-411.

Harvey, D. H., et al. (2024). Glucocorticoid-induced ocular hypertension and glaucoma. Clinical Ophthalmology, 18, 481-505.

Kasetti, R. B., et al. (2018). Transforming growth factor-beta2 (TGF-β2) signaling plays a key role in glucocorticoid-induced ocular hypertension. Journal of Biological Chemistry, 293(25), 9854-9868.

Kersey, J. P., & Bradway, D. C. (2006). Corticosteroid-induced glaucoma: A review of the literature. Eye, 20, 407-416.

Krag, S., et al. (2021). Risk of ocular hypertension in children treated with systemic glucocorticoids. Acta Ophthalmologica, 99(8), e1430-e1434.

Li, G., et al. (2019). In vivo measurement of trabecular meshwork stiffness in a corticosteroid-induced ocular hypertensive mouse model. Proceedings of the National Academy of Sciences of the USA, 116(5), 1714-1722.

Liang, X., et al. (2022). Identification of proteomic changes for dexamethasone-induced ocular hypertension using a tandem mass tag (TMT) approach. Experimental Eye Research, 216, 108914.

Nuyen, B., et al. (2017). Steroid-induced glaucoma in the pediatric population. Journal of the American Association for Pediatric Ophthalmology and Strabismus, 21(1), 1-6.

Patel, G. C., Millar, J. C., & Clark, A. F. (2019). Glucocorticoid receptor transactivation is required for glucocorticoid-induced ocular hypertension and glaucoma. Investigative Ophthalmology & Visual Science, 60(6), 1967-1978.

Raj, P., et al. (2021). Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: A Zambian perspective. Pan African Medical Journal, 39, 108.

Roberti, G., et al. (2020). Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Survey of Ophthalmology, 65(4), 458-472.

Stein, J. D., Khawaja, A., & Weizer, J. S. (2021). Glaucoma in adults: Screening, diagnosis, and management: A review. JAMA, 325(2), 164-174.

Storey, P. P., et al. (2020). Ocular hypertension after intravitreal injection of 2-mg triamcinolone. Retina, 40(1), 75-79.

Sugali, C. K., et al. (2021). The canonical Wnt signaling pathway inhibits the glucocorticoid receptor signaling pathway in the trabecular meshwork. American Journal of Pathology, 191(6), 1020-1035.

Sugiyama, M., et al. (2019). Corticosteroid-induced glaucoma in pediatric patients with hematological malignancies. Pediatric Blood & Cancer, 66(12), e27977.

World Health Organization (WHO). (2019). World report on vision. Retrieved from https://iris.who.int/bitstream/handle/10665/328717/9789241516570-por.pdf

Zeng, W., et al. (2020). Mitochondria and autophagy dysfunction in glucocorticoid-induced ocular hypertension/glaucoma mouse model. Current Eye Research, 45(2), 190-198.

Downloads

Published

01/12/2024

How to Cite

VILELA, B. S. .; VILELA, L. S. .; RIBEIRO, J. S. O. .; MONTEIRO, I. de L. P. .; NOBRE, S. O. . Corticosteroid use and the risk of glaucoma: A systematic review. Research, Society and Development, [S. l.], v. 13, n. 12, p. e49131247453, 2024. DOI: 10.33448/rsd-v13i12.47453. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/47453. Acesso em: 5 jan. 2025.

Issue

Vol. 13 No. 12

Section

Health Sciences

License

Copyright (c) 2024 Beatriz Schiavoni Vilela; Luciana Schiavoni Vilela; Jheovanna Silva O. Ribeiro; Izabella de Lara Pereira Monteiro; Sabrina Oliveira Nobre

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.